



LATVIJAS JURAS MEDICINAS CENTRS JSC

**CONSOLIDATED INTERIM REPORT FOR THE 9 MONTHS OF 2010
PREPARED IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING
STANDARDS**

(Translation of the Latvian original)

LATVIJAS JURAS MEDICINAS CENTRS JSC
TABLE OF CONTENTS

	PAGE
INFORMATION ABOUT PARENT COMPANY	3
COUNCIL AND BOARD OF THE GROUP	4
MANAGEMENT REPORT	5
DECLARATION OF MANAGEMENT RESPONSIBILITY	6
CONSOLIDATED FINANCIAL STATEMENTS	7 - 11
CONSOLIDATED STATEMENT OF FINANCIAL POSITION	7 - 8
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME	9
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	10
CONSOLIDATED STATEMENT OF CASH FLOWS	11
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	12 - 21

LATVIJAS JURAS MEDICINAS CENTRS JSC
INFORMATION ABOUT PARENT COMPANY

COMPANY NAME: Latvijas juras medicinas centrs JSC

LEGAL STATUS: Joint stock company

REGISTRATION: Registered in Latvian Register of Enterprises at 27.08.2004.
Registration Number: 40003306807

LEGAL ADDRESS: 23, Patversmes str. 23, Riga, LV - 1005, Latvia

SHARES 800 000 shares with face value 1,00 LVL, int. al.:
798 800 public registered shares. ISIN
code:LV0000100741

1 200 registered shares listed in the register of the Board

MAJOR SHAREHOLDERS: Ilze Birka 17,5%
Martins Birks 17,5%
Ilze Aizsilniece 11,4%
Guna Shvarcberga 10,4%
Janis Birks 7,6%

REPORTING PERIOD: 1 January 2010 - 30 September 2010

AUDITORS NAME AND ADDRESS: System audit Ltd.
Licence No.53
Matisa str. 19-6
Riga, LV-1001
Latvia

**LATVIJAS JURAS MEDICINAS CENTRS JSC
COUNCIL AND BOARD OF THE GROUP**

Council of the Group

**Number of shares owned at
30.09.2010**

From April 30, 2008 till April 28, 2010

<u>Name</u>	<u>Position</u>	
Martins Birks	Chairman of the Council	
Viesturs Shilinsh	Member of the Council	
Austris Adumans	Vice-Chairman of the Council	till 15.12.2009
Antons Vjaters	Member of the Council	
Vladislavs Skrebelis	Member of the Council	

From April 28, 2010 till the consolidated financial statements signing day

Martins Birks	Chairman of the Council	140 000
Viesturs Shilinsh	Member of the Council	3 038
Ineta Gadzjus	Member of the Council	
Jevgenijs Kalejs	Member of the Council	
Uldis Osis	Member of the Council	

Board of the Group

Name Position

From August 18, 2009 till the consolidated financial statements signing day

Janis Birks	Chairman of the Board	60 883
Marta Aizsilniece	Member of the Board	1 344
Andris Vigants	Member of the Board	700

MANAGEMENT REPORT

In accordance with the paragraph 1 of Section 4 of the law "On Consolidated Annual Accounts" the joint stock company is under an obligation to prepare the consolidated annual report.

The consolidated financial report contains information concerning the current financial situation and future development of parent company JSC "Latvijas Juras medicinas centrs" (hereinafter referred to as LJMC) and its subsidiary company "Juras medicina" Ltd. (hereinafter referred to as JM).

This not audited consolidated financial report is prepared in accordance with International Financial Reporting Standards (IFRS) adopted by the European Union and is based on business continuation principle. The financial statements were drawn up in Latvian lats (LVL) and euros (EUR). The applied currency exchange rate is EUR/LVL 0.702804.

The current financial condition of the Group of companies and its development

The share of the parent company constitutes the dominant part of the group's assets, turnover and profits.

The loss before taxes of the parent company was -75 227 LVL.

The loss before taxes of subsidiary company was -03 773 LVL.

Important events that affected results of the Group's activities in reporting period

Patient demand for state-funded outpatient medical in the first half of 2010th significantly exceeded the funding quota. During the summer months are traditionally lower demand for medical services. Therefore during the first half year the exceeding of the state funding quota was tolerated by 294 000 LVL (3 month funding level). This enabled to maintain the patient attraction to the Latvian Maritime Medical Centre and to ensure smooth personnel utilized capacity in winter and in the summer vacation period. The exceeding of quota is partially compensated during the third quarter thanks to the increase in public funding. As a result, has reduced the amount of losses.

Endoscopy is relocated to new premises. New services are developed in endoscopy. In addition to capsule endoscopy is acquired enteroskop for small intestine examination. The patient care at home is rapidly evolving.

On the 12th March 2010th was organized scientific-practical conference "Family doctors, specialists and nurses cooperation in a healthy society", which was attended by more than 600 medical staff and viewed on the internet by more than 1,000 stakeholders.

In July 2010th an agreement is signed with the Health Economic Centre for European Regional Development Fund support in amount of 436 035 LVL for outpatient health services development project in the former hospital care housing at Patversmes street 23. The implementation of the project has begun.

The share price at the 01.01.10 was LVL 1,60, 31.03.10 - LVL 2,00; 30.06.10 - LVL 1,60; 30.09.10 - LVL 1,50

Important Events after the Balance Sheet Date

Future Development of the Group

Planned to develop outpatient care at Patversmes Street 23 area. The development of joint computerized information and accounting system will continue. That will provide precise details of the services rendered to patient; the medical information will be in a digital format, as well as perspective – integration into the e-health system. The Board is optimizing the company's organization adapting it to the ongoing changes in the health service structure and changing funding levels. The technical project of the former hospital care house reconstruction is planned to be complete in the December 2010.

Risk Management

On a regular basis the significant risks are assessed, involving a wide range of specialists. Measures are taken to mitigate the potential impact on business activities. During the year, the creditors have decreased by four times. Constantly, the Group's future development scenarios are reviewed based on the underlying and predictable market changes.

On behalf of the Group:

Chairman of the Board

Janis Birks

Member of the Board

Marta Aizsilniece

Member of the Board

Andris Vigants

Riga, 26 November, 2010.

LATVIJAS JURAS MEDICINAS CENTRS JSC
DECLARATION OF MANAGEMENT RESPONSIBILITY

Consolidated financial statements are prepared to the best on our knowledge in accordance with International Financial Reporting Standards adopted by the European Union. These financial statements give a true and fair view of the financial position of the Group and of its financial performance for the period ended 30 September 2010 in all essential aspects. In preparing those financial statements, management:

- selected suitable accounting policies and then apply them consistently;
- made judgments and estimates that are reasonable and prudent;
- prepared the financial statements on the going concern basis to presume that the Group will continue in business.

The Management Board is responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the Group and enable them to ensure that financial statements drawn up from them comply with International Financial Reporting Standards as adopted by EU. They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Chairman of the Board

Janis Birks

Member of the Board

Marta Aizsilniece

Member of the Board

Andris Vigants

Riga, 26 November, 2010.

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

	September 30, 2010 LVL	December 31, 2009 LVL	Note	September 30, 2009 LVL
ASSETS				
Current assets:				
Stocks				
Raw materials	56 780	52 236	4	53 069
Total stocks	56 780	52 236		53 069
Debtors:				
Trade debtors	279 387	140 378	5	173 538
Other debtors	47 524	30 148	6	69 805
Accruals	3 109	4 208	7	4 318
Total debtors	330 020	174 734		247 661
Cash funds	871 706	944 749	8	1 085 275
Total current assets	1 258 506	1 171 719		1 386 005
Long-term investments:				
Intangible assets:				
Other intangible (fixed) assets	4 561	7 946	2	9 505
Total intangible assets	4 561	7 946		9 505
Fixed assets:				
Land and buildings	1 363 637	1 477 211		3 429 030
Technological equipment and machines	434 487	484 832		527 851
Other fixed assets and inventory	71 680	66 751		74 243
Long term investments in rented fixed assets	4 086	-		-
Unfinished building objects	175 842	175 842		175 842
Advance payments for fixed assets	-	-		-
Total fixed assets:	2 049 732	2 204 636	2	4 206 966
Long-term financial assets:				
Participating interests in associated enterprises	126 919	126 919	3	134 603
Total financial assets:	126 919	126 919		134 603
Total long-term investments:	2 181 212	2 339 501		4 351 074
TOTAL ASSETS	3 439 718	3 511 220		5 737 079

The notes on pages 12-21 form an integral part of these financial statements.

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

	September 30, 2010	December 31, 2009	Note	September 30, 2009
LIABILITIES	LVL	LVL		LVL
Liabilities:				
Liabilities:				
Received advance payments	459	21	10	1 161
Due to customers and suppliers	44 793	26 805	11	208 180
Taxes and social security payments	68 029	69 532	12	75 833
Other payables	82 900	92 326	13	100 840
Recognized deferred tax liabilities	121 613	134 515	22	414 857
Total liabilities	317 794	323 199		800 871
Provisions for liabilities and charges:				
Provisions for vacations	96 600	96 600		188 566
Total provisions	96 600	96 600		188 566
Total liabilities	414 394	419 799		989 437
Equity capital:				
Share equity	800 000	800 000	9	800 000
Reserves:				
c) reserves provided by the Articles of Association	31 993	31 993		31 993
d) fixed asset's revaluation reserve	872 496	945 606		2 596 601
Retained earnings:				
a) brought forward from previous years	1 398 414	1 370 908		1 316 597
b) current year profit or loss	(78 974)	(58 507)		1 108
Total shareholders' equity	3 023 929	3 090 000		4 746 299
Non-controlling interest	1 395	1 421		1 343
Total equity capital	3 025 324	3 091 421		4 747 642
TOTAL EQUITY, PROVISIONS AND LIABILITIES	3 439 718	3 511 220		5 737 079
Current Ratio	3,96	3,63		1,73
Debt Ratio	0,12	0,12		0,17

The notes on pages 12-21 form an integral part of these financial statements.

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

	2009, 9 month period LVL	2010, 12 month period LVL	Note	2009, 9 month period LVL
Net sales	2 436 054	4 562 603	14	3 768 461
Cost of goods sold	(2 386 659)	(4 303 550)	15	(3 525 836)
Gross profit or loss	49 395	259 053		242 625
Administrative expenses	(209 927)	(392 126)	16	(311 450)
Other operating income	68 422	92 349	17	64 973
Other operating expenses	(1 845)	(4 021)	18	(2 802)
Income from investment in associates	-	(7 066)	19	618
Interest income and similar income	14 955	31 834	20	35 209
Profit (loss) before taxes	(79 000)	(19 977)		29 173
Corporate income tax	-	(38 625)	21	(28 146)
NET PROFIT OR LOSS	(79 000)	(58 602)		1 108
Other comprehensive income				
Gain (loss) on revaluation of properties excluding deferred tax	-	(1 604 751)	22	-
Other comprehensive income for the year, net of tax	-	(1 604 751)		-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	(79 000)	(1 663 353)		-
Profit attributable to				
Owners of LJMC	(78 974)	(58 507)		1 106
Non-controlling interest	(26)	(95)		2
	(79 000)	(58 602)		1 108
Total comprehensive income attributable to				
Owners of LJMC	-	(1 593 562)		-
Non-controlling interest	-	(11 189)		-
	-	(1 604 751)		-
Number of shares	800 000	800 000		800 000
Earnings per Share (EPS) (LVL)	-0,10	-0,07		-

The notes on pages 12-21 form an integral part of these financial statements.

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (LVL)
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

	Share capital	Reserves provided by the Articles of Association	Properties revaluation reserve	Previous years retained earnings	Current year profit	Non-controlling interest	Total
At 31 December 2008	800 000	31 993	2 735 327	1 152 798	498	1 516	4 722 132
Previous years retained earnings	-	-	-	498	(498)	-	-
Dividends paid	-	-	-	-	-	-	-
Total comprehensive income for the year	-	-	(1 604 751)	-	(58 507)	(95)	(1 663 353)
Depreciation of revaluation surplus	-	-	(217 612)	217 612	-	-	-
Deffered tax on revaluation surplus	-	-	32 642	-	-	-	32 642
At 31 December 2009	800 000	31 993	945 606	1 370 908	(58 507)	1 421	3 091 421
Previous years retained earnings	-	-	-	(58 507)	58 507	-	-
Depreciation of revaluation surplus	-	-	(86 013)	86 013	-	-	-
Deffered tax on revaluation surplus	-	-	12 903	-	-	-	12 903
Total comprehensive income for the year	-	-	-	-	(78 974)	(26)	(79 000)
Non-controlling interest changes	-	-	-	-	-	-	-
At 30 September 2010	800 000	31 993	872 496	1 398 414	(78 974)	1 395	3 025 324

The notes on pages 12-21 form an integral part of these financial statements.

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

	2009, 9 month period LVL	2010, 12 month period LVL	Note	2009, 9 month period
Cash flows used in operating activities				
Net income before tax	(79 000)	(19 977)		29 173
Adjustments:				
a) depreciation of tangibles	274 215	465 189	2	349 038
b) depreciation of goodwill	3 385	5 097	2	3 877
c) provisions	-	(34 474)		57 492
d) loss (gain) on sale of tangibles	1 077	1 062		723
e) interest income	(31 834)	(31 834)	20	(35 209)
f) gain (loss) from investments in associates	-	7 066	19	(618)
2. Gain (loss) before changes in current assets and liabilities	167 843	392 129		404 476
Changes in operating assets and liabilities:				
a) receivables.	(192 953)	103 905		65 594
b) inventory.	(4 544)	35 231		34 398
c) current liabilities.	68 728	(532 837)		(366 817)
3. Gross operating cash flow	39 074	(1 572)		137 651
4. Paid corporate income tax.	(6 465)	(29 913)	12	(33 714)
5. Net cash used in operating activities	32 609	(31 485)		103 937
II. Cash flow used in investment activities				
1. Purchase of shares of associates.	-	(618)		(618)
2. Purchase of fixed assets.	(120 607)	(92 501)	2	(90 739)
3. Selling of fixed assets.	-	33		-
4. Received interest.	14 955	31 834	20	35 209
5. Net cash from investment activities	(105 652)	(61 252)		(56 148)
III. Cash flows used in financing activities				
1. Paid dividends.	-	-		-
2. Net cash from financing activities	-	-		-
IV. Net increase (decrease) in cash	(73 043)	(92 737)		47 789
V. Cash at the beginning of the period	944 749	1 037 486		1 037 486
VI. Cash at the end of the period	871 706	944 749		1 085 275

The notes on pages 12-21 form an integral part of these financial statements.

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

GENERAL INFORMATION

“Latvijas Juras Medicinas Centrs” is a joint-stock company (the Company) incorporated in the Republic of Latvia on 27 August 1996. The consolidated financial statements incorporate the financial statements of the Company and its subsidiary - "Juras medicina" Ltd. (the Group).

The Group's main activity is health care services.

1. ACCOUNTING PRINCIPLES

Basis of consolidation

The consolidated financial statements have been prepared in accordance with the International financial reporting standards adopted by the European Union. Enclosed financial statements are prepared in the national currency of Latvia, the lats (LVL).

There is no difference in balance sheet dates of the Company and its subsidiary.

The interest of minority shareholders is stated at the minority proportion of the net assets.

All significant intercompany transactions and balances among Group companies are eliminated on consolidation.

The portion attributed to the parent company of the net assets are offset with the investment and have been eliminated. The portion attributed to the parent company of the retained earnings earned after the acquisition date of shares are included in the consolidated retained earnings.

Foreign currency

Transactions denominated in foreign currencies are converted into Lats at the official exchange rate of the Bank of Latvia at the date of transaction. Monetary assets and liabilities are converted at the Bank of Latvia rate at the balance sheet date.

The applicable rate used for the principal currencies were the follows:

	September 30, 2010	December 31, 2009
EUR	0,702804	0,702804
USD	0,517	0,489

Gains or losses on conversion are posted to the profit or loss account at the Bank of Latvia official exchange rate as of the balance sheet date and recognized in the period when they incurred.

Exchange differences rising on the settlement of monetary items are recognised in the period in which they arise.

Cash and cash equivalents

Cash includes cash on hand and demand deposits with credit institutions. The statement on cash flow is prepared using indirect method, making adjustments affecting the net profit reconciling with the changes in cash during the year.

Trade receivables

Trade receivables are stated at their net realizable value. Trade receivables represent the gross balance due from customers less provision, if any, for doubtful accounts receivable. Provision for doubtful accounts receivable at the balance sheet date represents the estimated amounts of probable losses that might have been incurred at the balance sheet date based on individual evaluation of each debtor.

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

Inventory

Inventories are stated at the lower of cost or market, using FIFO method.

Fixed assets

Fixed assets excluding real estate are stated at historical cost, less accumulated depreciation. The cost of the item comprises its purchase price, including import duties and any directly attributable costs of bringing the asset to working condition for intended use. The cost of self-constructed asset is determined using the same principles as for an acquired asset. Only assets with its useful life more than one year are capitalized. Depreciation is calculated based on the historical cost.

Repair and maintenance costs are expensed when incurred. Capital expenditures such as refurbishment of buildings and improvements to structural elements are recognized as an asset if the expenditures improve the condition of the asset beyond its original estimated life.

Land and buildings (real estate) are accounted according to the revaluation model, recognized at the fair value determined from market-based evidence. Buildings are revaluated as on 31.12.2009 based on the cadastral value as fair value. Accumulated depreciation at the date of the revaluation is eliminated against the gross carrying amount of the asset and the net amount restated to the revalued amount of the asset. Depreciation is calculated based on the revalued amount. The depreciation charge for each period is recognised in the statement of income.

The increase (decrease) in the value of buildings and constructions is reflected in the Statement of comprehensive income under "Gains (losses) from revaluation of properties". Revaluation decreases are charged first against the revaluation surplus in equity related to the specific asset, and any excess against profit or loss.

Depreciation is provided on all fixed assets based on historical cost. Depreciation on fixed assets are computed using the straight-line method over the estimated average useful lives:

Buildings:	20 years
Revaluated part of the buildings	15 years
Machinery and equipment:	3 years
Other fixed assets:	5 years

For tax purposes, depreciation on tangible fixed assets is calculated under the double declining balance method over the period established in accordance with prevailing tax legislation.

Investments in associates

Investments in associates are initially recognized at the cost and then accounted under the equity method.

Revenue recognition

Sales of goods are recognized when goods are delivered and title has passed.

Dividends

Dividends are recognized as liabilities in the Group financial statements after the Group shareholders made a decision to pay.

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

Property revaluation surplus

The revaluation surplus is included in other comprehensive income and accrued amount is reflected in equity under the heading "Investment revaluation reserve". According to IASs 16, p.41, the revaluation surplus included in equity is transferred directly to retained earnings. The surplus transferred is the difference between depreciation based on the revalued carrying amount of the asset and depreciation based on the asset's original cost. Transfers from revaluation surplus to retained earnings are not made through profit or loss.

Taxation

Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in opinion of management, it is more likely than not that some proportion or all deferred tax assets will not be realized.

Deferred tax on revaluation surplus is reflected in the Statement of other comprehensive income.

Risk Management

The Management Board is responsible for setting up risk management guidelines and risk monitoring.

The Group has identified the major risk factors and developed policies and mechanisms to control these factors. The major risks are defined as:

Market risk: a country's economic deterioration, changes in the public and the insurer health care and its financing policy, competition, changes in utility tariffs, etc. can significantly affect the demand for Groups services and its profitability.

Operational risk: The possibility of suffering losses caused by inadequate or failed internal pace of the medical treatment process, actions of staff or systems, or external events impact. Patient dissatisfaction with the quality of medical services, treatment process organization or staff attitudes in the long term can lead to a fall in income and even financial claims.

Credit Risk: The inability of insurance companies and patients to pay for the services in time and in full amount.

Liquidity risk: unable to meet the legally enforceable requirements without major damage and inability to cope with unplanned changes in Groups resources and / or market conditions related to the fact that it does not have sufficient liquid assets.

Risk control mechanisms include: appropriate risk policies, investment planning, cash flow planning, budgeting and control, liquidity control, the medical treatment process organization and control, sanitary compliance control, staff skill development, implementation of advanced technologies, employee involvement in risk assessment and control.

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

2 TOTAL FIXED ASSETS: AND OTHER INTANGIBLE (FIXED) ASSETS

As of 30 September 2010 and 31 December 2009
fixed assets are composed as follows: (LVL)

LVL	Intangible assets	Land & buildings	Investment assets	Machinery and equipment	Other fixed assets	Long-term investments in rented fixed assets	Advance payments for fixed assets	Unfinished building objects	Total
Historical cost									
At 31 December									
2008	25 932	4 351 402	-	1 956 874	389 939	-	13 249	175 842	6 913 238
Additions	686	34 811	-	16 098	11 771	-	29 135	-	92 501
Transfers	-	(1 845 558)	-	-	-	-	(42 384)	-	(1 887 942)
Disposals	(546)	-	-	(26 842)	(58 416)	-	-	-	(85 804)
At 31 December									
2009	26 072	2 540 655	-	1 946 130	343 294	-	-	175 842	5 031 993
Additions	-	-	-	83 837	32 684	4 086	-	-	120 607
Transfers	-	-	-	-	-	-	-	-	-
Revaluation Disposals or change of classification	-	-	-	(158 099)	(11 638)	-	-	-	(169 737)
At 30 September									
2010	26 072	2 540 655	-	1 871 868	364 340	4 086	-	175 842	4 982 863
Accumulated depreciation									
At 31 December									
2008	13 236	811 986	-	1 309 860	298 752	-	-	-	2 433 834
Charge for the year	5 097	33 846	-	178 227	35 504	-	-	-	252 674
Charge for the period for revaluated fixed assets	-	217 612	-	-	-	-	-	-	217 612
Disposals	(207)	-	-	(26 789)	(57 713)	-	-	-	(84 709)
At 31 December									
2009	18 126	1 063 444	-	1 461 298	276 543	-	-	-	2 819 411
Charge for the period	3 385	27 561	-	133 350	27 291	-	-	-	191 587
Charge for the period for revaluated fixed assets	-	86 013	-	-	-	-	-	-	86 013
Disposals or change of classification	-	-	-	(157 267)	(11 174)	-	-	-	(168 441)
At 30 September									
2010	21 511	1 177 018	-	1 437 381	292 660	-	-	-	2 928 570
Net book value									
At 31 December									
2008	12 696	3 539 416	-	647 014	91 187	-	13 249	175 842	4 479 404
At 31 December									
2009	7 946	1 477 211	-	484 832	66 751	-	-	175 842	2 212 582
At 30 September									
2010	4 561	1 363 637	-	434 487	71 680	4 086	-	175 842	2 054 293

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

3 PARTICIPATING INTERESTS IN ASSOCIATED ENTERPRISES

	Capital share (%)	Amount of investment 2010 LVL	Capital share (%)	Amount of investment 2009 LVL
Participating interests in associated enterprises				
Participation in "Neirozu klinika" Ltd.	45	126 919	45	126 919
Total participating interests in associated enterprises		126 919		126 919

4 RAW MATERIALS

	2010 LVL	2009 LVL
Pharmaceutical	45 855	48 246
Stock in warehouse	187	2 136
Inventory	51	470
Products	263	409
Furniture	-	-
Other materials	10 142	713
Advance payments to supplier of goods	282	262
Total	56 780	52 236

5 DUE FROM CUSTOMERS

	2010 LVL	2009 LVL
Rigas department	219 745	41 574
Likvidējamā RSK apdrošināšanas sabiedrība	11 334	29 009
Gjesidege Baltic	1 358	11 664
BTA AAS	3 419	11 182
IF Latvija AAS	3 456	10 462
Latvian University	2 203	8 286
SEESAM Latvija	1 094	8 018
Balta AAS	2 272	7 223
Balva AAS	277	5 218
Narkologijas centrs	7 491	2 861
Baltijas apdrošināšanas nams	1 616	2 245
Compensa Life Vienna Insurance group	71	1 786
NBS militaras medicinas centrs	-	1 637
Ministry of Interior – health and social department	539	1 367
Ergo Latvija AAS	2 177	1 310
Biogen Idec Ltd.	1 477	1 168
Evolution Latvia	-	-
Merck sharp	-	-
Accrued income	-	-
Other customers	22 173	9 405
Bad debt provisions	(1 315)	(14 037)
Total	279 387	140 378

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

6 OTHER RECEIVABLES

	2010	2009
	LVL	LVL
Taxes overpayment (note No.12)	34 301	23 759
VAT for unpaid invoices	70	4 320
Other debtors	13 153	2 069
Total	<u>47 524</u>	<u>30 148</u>

7 DIFFERED EXPENSES

	2010	2009
	LVL	LVL
Assurance expense	3 109	4 208
Riga Stock Exchange, shares quotation	-	
Other expense	-	
Total	<u>3 109</u>	<u>4 208</u>

8 CASH

	2010	2009
	LVL	LVL
Cash in banks	865 813	911 533
Deposit		29 803
Cash on hands	5 893	3 413
Total	<u>871 706</u>	<u>944 749</u>

9 SHARE CAPITAL

	2010	2010	2009	2009
Shareholders:	Number of	Share %	Number of	Share %
	shares		shares	
Janis Birks	60 883	7,6%	60 883	7,6%
Ilze Birka	140 000	17,5%	140 000	17,5%
Martins Birks	140 000	17,5%	140 000	17,5%
Ilze Aizsiliece	91 565	11,4%	91 565	11,4%
Guna Shvarcberga	82 917	10,4%	82 917	10,4%
Other shareholders (shares less than 5%)	284 635	35,6%	284 635	35,6%
Total	<u>800 000</u>	<u>100,0%</u>	<u>800 000</u>	<u>100,0%</u>

10 DUE TO RECEIVED ADVANCE PAYMENTS

	2010	2009
	LVL	LVL
VOAVA advance payment for 2009	-	
Other advances	459	21
Total	<u>459</u>	<u>21</u>

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

11 DUE TO SUPPLIERS AND CONTRACTORS

	2010	2009
	LVL	LVL
Amerilat MD	-	5 051
Latvijas Gaze	-	4 392
Latvenergo Rīgas elektrotīkls	-	4 340
Sistēmu Audits SIA	-	2 420
Latvian University	-	1 924
Rīgas Ūdens	-	979
Academic histologic laboratory	-	726
Lattelekom	-	503
AB Medical Group Rīga	-	225
Recipe Plus SIA	-	-
B.Braun SIA	1 417	-
Tradintek SIA	15 320	-
Olympus Latvia SIA	-	-
Other suppliers	28 056	6 245
Total	<u>44 793</u>	<u>26 805</u>

12 TAXES

	As of 31-12- 2008	Calculated	Paid	Transfer	As of 30- 09-2010
Value added tax	948	26 647	(24 952)	-	2 643
Social insurance	42 925	415 488	(419 680)	-	38 733
Personal income tax	25 352	276 120	(274 905)	-	26 567
Corporate income tax	(22 062)	-	(6 465)	-	(28 527)
Unemployment duty	80	780	(774)	-	86
Natural resources tax	227	-	(339)	-	(112)
Real estate tax	(1 697)	308	(4 273)	-	(5 662)
Total, including	<u>45 773</u>	<u>719 343</u>	<u>(731 388)</u>	<u>-</u>	<u>33 728</u>
due to the budget	69 532				68 029
overpayment	(23 759)				(34 301)

13 DUE TO OTHER COMPANIES

	2010	2009
	LVL	LVL
Salaries	81 807	90 610
Deposited salary	451	733
Trade union	642	983
Total	<u>82 900</u>	<u>92 326</u>

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

14 NET SALES

	2010 LVL	2009 LVL
Medical ambulant services	1 511 582	1 791 857
Medical hospital services	554 272	1 722 868
Insurance payments	186 955	606 894
VS ZDC ambulant services	96 347	174 924
Services - minimum fixed part	6 929	88 636
Residents training	24 512	64 422
Stomatology services	29 405	43 625
Family doctors	24 077	37 229
Other income	1 975	32 148
Total	<u>2 436 054</u>	<u>4 562 603</u>

15 COST OF GOODS SOLD

	2010 LVL	2009 LVL
Salaries and	1 151 342	1 937 133
Medical goods	270 455	625 705
Fixed assets depreciation	277 600	470 286
Social tax	269 001	446 676
VAT - expenses	101 876	169 509
Public utilities	72 725	134 729
Rent of equipment	42 730	97 356
Repair expenses	42 328	64 523
Household goods	23 880	41 374
Computer maintenance, repair	10 136	23 545
Security expenses	17 946	21 175
Utilities	7 109	12 629
Current assets write-off	16 317	37 257
Feeding expenses	9 637	33 211
Medical researches	12 098	30 551
Employees trainings	920	28 368
Advertising	17 690	18 682
Gifts to employees	599	18 587
Accruals for vacations	(12 723)	14 327
Office expenses	3 763	9 295
Transport expense	3 361	6 612
Insurance expenses	3 648	4 821
Allowances to employees	1 340	2 650
Unemployment duty	774	1 272
Received discounts	(3 656)	(7 643)
Other operating expenses	45 763	60 920
Total	<u>2 386 659</u>	<u>4 303 550</u>

LATVIJAS JURAS MEDICINAS CENTRS JSC
 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

16 ADMINISTRATIVE EXPENSES

	2010	2009
	LVL	LVL
Salaries and wages	112 279	203 954
Social tax	24 524	47 562
Board remuneration	14 454	33 645
Board chairperson remuneration	12 685	31 679
Communication expenses	9 087	17 210
Council members remuneration	8 960	13 328
Sakaru izdevumi	2 810	7 942
Office expenses	9 168	6 411
Chairperson of the Board social tax	3 056	6 766
Council chairperson remuneration	4 320	5 760
Audit expenses	-	5 000
Council members social tax	2 027	3 019
Presentation expenses	1 487	3 634
Bank expenses	2 642	2 698
Other administrative expenses	1 337	1 965
Chairperson of the Council social tax	1 041	1 388
Legal services	50	165
Total	<u>209 927</u>	<u>392 126</u>

17 OTHER OPERATING INCOME

	2010	2009
	LVL	LVL
Rent income	48 676	66 466
Income from social tax return	-	8 688
Press goods	-	2 855
Solarium income	485	1 363
Laundry income	738	911
Feeding income	999	745
Other income	17 524	11 321
Total	<u>68 422</u>	<u>92 349</u>

18 OTHER OPERATING EXPENSES

	2010	2009
	LVL	LVL
Currency exchange loss	7	499
Loss from fixed assets disposals	1 077	1 062
Penalties	16	1 042
Real estate tax	-	63
Other expenses	745	1 355
Total	<u>1 845</u>	<u>4 021</u>

19 INCOME FROM INVESTMENT IN ASSOCIATES

	2010	2009
	LVL	LVL
Neurology clinic Ltd.	-	(7 066)
Total	<u>-</u>	<u>(7 066)</u>

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 30 SEPTEMBER 2010 AND 31 DECEMBER 2009

20 INTEREST INCOME AND SIMILAR INCOME

	2010	2009
	LVL	LVL
Interest income	14 955	31 834
Total	<u>14 955</u>	<u>31 834</u>

21 CORPORATE INCOME TAX

	2010	2009
	LVL	LVL
Calculated Corporate income tax	-	36 239
Deferred Corporate income tax	-	2 386
Total	<u>-</u>	<u>38 625</u>

21 CORPORATE INCOME TAX (CONTINUED ...)

	2010	2009
	LVL	LVL
Profit (loss) before tax	-79 000	-19 977
Theoretically calculated corporate income	-	-
Permanent differences	-	36 239
Calculated corporate income tax	-	36 239

Deffered tax

Temporary difference between financial	(269 866)	(269 866)
Temporary difference of fixed assets revaluation	(637 389)	(723 402)
Accruals for vacations	96 503	96 503
Accrued liabilities	-	-
Total temporary differences	<u>(810 752)</u>	<u>(896 765)</u>
Tax rate applied	15%	15%
Deferred tax liabilities	<u>121 613</u>	<u>134 515</u>
Recognized deferred tax liabilities	<u>121 613</u>	<u>134 515</u>

22 PROPERTIES REVALUATION RESERVE

Balance at beginning of year	2 735 327	2 735 327
Other comprehensive income:	-	-
Decrease arising on revaluation of properties	(1 887 942)	(1 887 942)
Deferred tax assets arising on revaluation	283 191	283 191
Depreciation on evaluation surplus	(217 612)	(217 612)
Reversal of deferred tax liability on revaluation	32 642	32 642
Balance at end of year	<u>945 606</u>	<u>945 606</u>
